Biotech | March 12, 2024
USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
It is the first autotaxin inhibitor to be investigated in cancer patients
It is the first autotaxin inhibitor to be investigated in cancer patients
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
The company will manufacture a cancer immunotherapy product from 2022
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Subscribe To Our Newsletter & Stay Updated
